Novartis India Limited has received and disclosed a Form C filing from Novartis AG, its erstwhile promoter, pursuant to Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The disclosure pertains to a significant change in ownership structure. Novartis AG has sold its entire shareholding in Novartis India Limited. The transaction details are as follows:
Transaction Details:
- Seller: Novartis AG (Promoter)
- Number of Shares Sold: 1,74,50,680 (One Crore Seventy-Four Lakhs Fifty Thousand Six Hundred and Eighty) equity shares
- Percentage of Share Capital: 70.68% (Seventy point Sixty-Eight percent)
- Transaction Type: Sale
- Transaction Value: ₹13,76,88,87,281 (Indian Rupees One Thousand Three Hundred Seventy-Six Crore Eighty-Eight Lakh Eighty-Seven Thousand Two Hundred Eighty-One)
- Mode of Disposal: Off-market sale
- Date of Transaction: July 29, 2026
- Exchange: Not applicable (NA) for this off-market transaction
Ownership Change:
- Pre-transaction Holding: 1,74,50,680 shares (70.68%)
- Post-transaction Holding: Nil (0 shares)
Regulatory Compliance:
- The disclosure was received by Novartis India Limited on Wednesday, July 29, 2026.
- The filing was made in accordance with Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
- The company has made this information available on its website at www.nilpharma.co.in.
Additional Information:
- The value of transaction excludes taxes, brokerage, and any other charges.
- No trading in derivatives on the company's securities was reported by Novartis AG.
- The disclosure was signed by Oliver Watson as an Authorized Signatory of Novartis AG.
- The company's compliance officer, Chandni Maru (Company Secretary), signed the submission to BSE.